The University of Southampton
University of Southampton Institutional Repository

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial
Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial
A retrospective analysis of children with first relapse of acute lymphoblastic leukaemia (ALL), treated on the UKALL R2 protocol at four different hospitals, between June 1995 and December 2002 was performed. Of the 150 children 139 (93%) achieved a second complete remission. The overall survival (OS) and event-free survival (EFS) for the whole group was 56% and 47% respectively. The duration of first complete remission and immunophenotype, but not sites of relapse, were predictive for survival. Using the Berlin–Frankfürt–Münster risk stratification for relapsed ALL, the OS and EFS for standard, intermediate (IR) and high risk (HR) groups were 92% and 92%, 64% and 51%, and 14% and 15%, respectively; P < 0·0001 for both OS and EFS. In the IR group, those with a very early isolated central nervous system relapse also had a significantly worse outcome (P = 0·0001). Given the poor outcome of a second relapse, clear strategies are required to identify those in the IR group who will most benefit from stem cell transplantation (SCT). A higher proportion (16%) of induction failures in the HR group suggest the need for novel agents during this phase of treatment, but SCT was associated with a lower relapse rate and better outcome than those treated with chemotherapy alone.
67-75
Roy, A.
023648ec-2915-4a04-abdf-38e200a5308a
Cargill, A.
41abe614-0e56-4cca-ac98-3b42d6d78ad4
Love, S.
de3ec24d-be42-4ca4-967d-b05436b6adc9
Moorman, A.V.
af5027f3-4927-4e62-b1be-ac4bdcf6cd8f
Stoneham, S.
3ec5b14d-a47c-4a67-b73d-0bcd46bf8374
Lim, A.
5d5b1699-7084-48e8-b7df-48242c8edcda
Darbyshire, P.J.
b08ab60d-951b-4cf9-9b26-aaa74cc1a1b4
Lancaster, D.
285ce1da-605f-4a93-8a3b-2b726254a6f0
Hann, I.
f1d42768-064e-4663-b855-fa2206f2e05d
Eden, T.
1ab691c3-0e37-43ea-8fa0-5397d5463c69
Saha, V.
629475ea-2b52-410e-8564-a658ce0a811c
Roy, A.
023648ec-2915-4a04-abdf-38e200a5308a
Cargill, A.
41abe614-0e56-4cca-ac98-3b42d6d78ad4
Love, S.
de3ec24d-be42-4ca4-967d-b05436b6adc9
Moorman, A.V.
af5027f3-4927-4e62-b1be-ac4bdcf6cd8f
Stoneham, S.
3ec5b14d-a47c-4a67-b73d-0bcd46bf8374
Lim, A.
5d5b1699-7084-48e8-b7df-48242c8edcda
Darbyshire, P.J.
b08ab60d-951b-4cf9-9b26-aaa74cc1a1b4
Lancaster, D.
285ce1da-605f-4a93-8a3b-2b726254a6f0
Hann, I.
f1d42768-064e-4663-b855-fa2206f2e05d
Eden, T.
1ab691c3-0e37-43ea-8fa0-5397d5463c69
Saha, V.
629475ea-2b52-410e-8564-a658ce0a811c

Roy, A., Cargill, A., Love, S., Moorman, A.V., Stoneham, S., Lim, A., Darbyshire, P.J., Lancaster, D., Hann, I., Eden, T. and Saha, V. (2005) Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. British Journal of Haematology, 130 (1), 67-75. (doi:10.1111/j.1365-2141.2005.05572.x).

Record type: Article

Abstract

A retrospective analysis of children with first relapse of acute lymphoblastic leukaemia (ALL), treated on the UKALL R2 protocol at four different hospitals, between June 1995 and December 2002 was performed. Of the 150 children 139 (93%) achieved a second complete remission. The overall survival (OS) and event-free survival (EFS) for the whole group was 56% and 47% respectively. The duration of first complete remission and immunophenotype, but not sites of relapse, were predictive for survival. Using the Berlin–Frankfürt–Münster risk stratification for relapsed ALL, the OS and EFS for standard, intermediate (IR) and high risk (HR) groups were 92% and 92%, 64% and 51%, and 14% and 15%, respectively; P < 0·0001 for both OS and EFS. In the IR group, those with a very early isolated central nervous system relapse also had a significantly worse outcome (P = 0·0001). Given the poor outcome of a second relapse, clear strategies are required to identify those in the IR group who will most benefit from stem cell transplantation (SCT). A higher proportion (16%) of induction failures in the HR group suggest the need for novel agents during this phase of treatment, but SCT was associated with a lower relapse rate and better outcome than those treated with chemotherapy alone.

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 26581
URI: http://eprints.soton.ac.uk/id/eprint/26581
PURE UUID: 80a29425-9ecb-460b-90d5-e68e6a21215e

Catalogue record

Date deposited: 19 Apr 2006
Last modified: 15 Mar 2024 07:12

Export record

Altmetrics

Contributors

Author: A. Roy
Author: A. Cargill
Author: S. Love
Author: A.V. Moorman
Author: S. Stoneham
Author: A. Lim
Author: P.J. Darbyshire
Author: D. Lancaster
Author: I. Hann
Author: T. Eden
Author: V. Saha

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×